Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

The meeting cancellation came one day before the CDC issued its weekly MMWR report, a scientific update on the latest ...

Most people will recover from viruses like the flu, COVID, and RSV without medical care, but some patients might need a trip ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...

In a small study, Yale researchers have found "differences in immune profiles" among those who have rare reaction to the ...

Scientists explored the differences in heart inflammation caused by COVID-19, anti-COVID-19 vaccines, and other viral ...

FDA's reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent ...

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...